The rise in the importance of out-sourcing has been one of the most dramatic changes in the drug discovery landscape over the past 20 years.
Discovery Analytical Consulting (DAC) has established a consortium of companies to address the need for flexible drug discovery services. Via our network of providers, we provide a range of physical chemistry, in vivo efficacy, PK and bioanalytical services supported by experienced study management and consultancy including expert DMPK interpretation.
Our core values include being highly responsive to client needs. No individual part of the consortium is so big as to have forgotten how important this is. A consistent, single point of contact provides the ongoing continuity that is crucial to providing efficient support. Above all, regular and open communication is provided at all times to ensure a successful collaboration. We recognise the headaches that can be associated with large volumes of data and will format your data to meet your reporting needs.
Discovery Analytical Consulting (DAC) and Bio-Mimetic Chromatography Consultancy (BMCC), which is owned and run by Professor Klara Valko, are working together to support drug discovery projects and promote the use of HPLC for biomimetic property measurements.
Bio-mimetic chromatography involves the use of human proteins and phospholipid to model the in vivo distribution of compounds. It allows researchers to better understand their candidates' in vivo distribution for the optimisation of candidate selection meaning fewer costly animal tests on compounds likely to fail due to poor efficacy or toxicity. More information on drug efficiency can help with early dose estimation.
BMCC's services include:
- Measurement of compound physchem properties, in vivo distribution prediction via measurement of compound affinity for IAM, HSA and AGP; to provide drug efficiency and dose predictio
- Support, advice and data analysis to help set up bio-mimetic chromatography testing and measurement in-house and advice for early drug discovery projects
- Training Courses on HPLC, lipophilicity, bio-mimetic chromatography and other applications of chromatography for successful drug discovery
- Lead Optimisation support to help you select and improve the best candidates to achieve your aims.
For a copy of Klara Valko's latest article on the use of Bio-mimetic chromatography to estimate in vivo distribution and its applications in early drug discovery or to discuss how Bio-mimetic chromatography can benefit your discovery programmes, please contact me below...
CEMAS Ltd Bioanalytical support
Discovery Analytical Consulting (DAC) and CEM Analytical Services (CEMAS) work together to provide bioanalysis solutions in the drug discovery arena. This can either be stand-alone bioanalytical support or integrated with a broad range of pharmacokinetic and in vivo efficacy services available through our preferred supplier Saretius Limited.
CEMAS is a long established and dynamic contract analytical company providing method development and bioanalysis from discovery through to phase III clinical trials to companies requiring affordable and flexible support. DAC offers a range of consulting services for discovery analytical chemistry, compound management and external study management. Both CEMAS and DAC are based in south east England, close to major transport networks, and we fully understand the needs of companies of all sizes, the issues confronting them and the importance of ongoing communication.
All CEMAS activities are backed by comprehensive in-house method development, validation and transfer know-how. The company has the capacity to carry out large-scale sample analysis with full accreditation to GLP, GMP and GCP, where required. Sample and equipment details are as follows:
Animal and Human biological fluids and tissues analysed in all formats
Automated High Throughput systems
9x AB Sciex LC-MS/MS including 4x API 5500
2x Spark Holland Pharma automated SPE systems
3x Agilent 6890/5973 GC-MS
1x Agilent 7800 ICP-MS
Data formatted to meet customer reporting needs
CEMAS has highly skilled scientists using excellent equipment and the commitment to invest more when necessary. This high quality leads on to greater reliability and a reduction in costs for large volumes.
Please contact me below for further information regarding our capabilities, capacities, procedures and pricing, or to discuss how we can further assist in your out-sourcing of bioanalysis and other studies.
Abundnz offers advanced analytical solutions for biotechnology, pharmaceutical and diagnostic companies as well as supporting life sciences research. They specialize in the bioanalysis of innovative medicines such as peptide and protein drugs, oligonucleotides and nanomedicines using LC-MS. Their expertise includes the measurement of analytes at extremely low concentrations in complex matrices with small sample volumes using high end separation and detection technologies. Abundnz has developed a unique ultrasensitive assay (pAMS) for bioanalytical studies with large molecule drugs. They also offer biological assays, immunoassays, imaging MS, histopathology, cell separations and in vitro systems for preclinical drug research through associate company Immundnz.
Abundnz's services include:
- Bioanalysis - LC-MS, ELISA, pAMS
- Product characterisation – intact mass, amino acid sequence, modifications, impurity profiling
- Protein biomarker discovery and validation
- Epitope mapping
- Biological and analytical assay development
- Intracellular drug localization and quantitation
- in vitro systems
For further information regarding these services and how we can help to support your research programmes, please contact me below.
Discovery Analytical Consulting works with deltaDOT Ltd to promote their unique High Performance Capillary Electrophoresis (HPCE) technology for Drug Discovery, Biotechnology and other applications. deltaDOT is a spin out company from Imperial College, London that designs and produces HPCE instruments and uses them to provide Analytical Services and Contract Research from its laboratories at the London Bioscience Innovation Centre (LBIC).
HPCE analysis is available as a clear alternative to chromatography for the solution of analytical challenges for a wide range of analytes including:
- Amino Acids
- Nucleic Acids
- Chiral Molecules
The key to deltaDOT’s technology is their patented imaging and analysis technology, Label Free Intrinsic Imaging (LFII®), which uses a multipoint detection system (512 detection points, each sampling at around 10Hz) to track the passage of analyte bands across the detection window and proprietary algorithms for the processing of the acquired signals to eliminate background noise leading to higher quality data in terms of sensitivity, resolution, quantification and repeatability. A factor of 10 increase in signal-to-noise compared to conventional systems is typically observed.
To request a sample submission form and/or a full list of what's available, or to discuss what HPCE can do to solve your analytical challenges, please contact me below...
MIP Diagnostics Limited
Discovery Analytical Consulting works in partnership with MIP Diagnostics Ltd to promote and support their revolutionary technology in the field of Molecularly Imprinted Polymers (MIPs).
MIPs are Affinity Reagents (sometimes referred to as plastic antibodies) whose potential applications include:
- Extraction devices for chemical analysis
- Research tools for analysis of molecular disposition and interactions
- Sensors and assays, including tests of precision medicine and accompanying diagnostics
- Drug Delivery
MIP Diagnostics' proprietary technology affords a high degree of control over the polymerisation process and hence over the size of nanoparticle produced (30-300nm) with high uniformity of the binding site. Self-assembly of monomers around the target ensures high affinity and selectivity similar to antibodies but with major advantages in terms of their stability and robustness. MIPs withstand organic solvents and extremes of pH and temperature and hence can be used in applications that no antibody would survive.
With around 5000 monomers to choose from (compared to 20 amino acids) and using a mixture of computational and combinatorial techniques and in-house knowhow, MIPs can be prepared for almost any target ranging from very small molecules to viruses. No immune response is required and no animals are used. Initial development typically takes between 2 and 6 weeks with subsequent batches prepared in a matter of hours with very high reproducibility both in terms of their size and affinity. Functionalised particles (fluorescent, magnetic and others) are readily prepared.
Contact me below for further literature or to arrange a discussion about your application.
Quote promotion code DAC10 to receive an introductory discount of 10% on your first order.